Factors to guide the use of extended-release buprenorphine formulations for specific patient populations

References

• Barnett, A., Savic, M., Lintzeris, N., Bathish, R., Arunogiri, S., Dunlop, A. J., Haber, P., Graham, R., Hayes, V., & Lubman, D. I. (2021). Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients’ experiences in Australia. Drug and Alcohol Dependence, 227, 108959. https://doi.org/10.1016/j.drugalcdep.2021.108959
   PubMed Web of Science ®Google Scholar
• Bruneau, J., Ahamad, K., Goyer, M.-È., Poulin, G., Selby, P., Fischer, B., Wild, T. C., Wood, E., & CIHR Canadian Research Initiative in Substance Misuse. (2018). Management of opioid use disorders: A national clinical practice guideline. CMAJ: Canadian Medical Association Journal = Journal de l’Association Medicale Canadienne, 190(9), E247–E257. https://doi.org/10.1503/cmaj.170958
   PubMed Web of Science ®Google Scholar
• Chappuy, M., Meroueh, F., Trojak, B., Bachellier, J., Bendimerad, P., Kosim, M., Hjelmström, P., Nubukpo, P., Brousse, G., & Rolland, B. (2021). Factors of interest in extended-release buprenorphine: Comparisons between incarcerated and non-incarcerated patients with opioid use disorder. Patient Preference and Adherence, 15, 1259–1267. https://doi.org/10.2147/PPA.S311674
   PubMed Web of Science ®Google Scholar
• Cheng, A., Badolato, R., Segoshi, A., McDonald, R., Malone, M., Vasudevan, K., Badiei, B., Sugarman, A., Macdonald, R., Mangat, J., Giftos, J., Lee, J. D., & Tofighi, B. (2022). Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: An in-depth qualitative study. Addiction Science & Clinical Practice, 17(1), 4. https://doi.org/10.1186/s13722-022-00288-4
   PubMed Web of Science ®Google Scholar
• Cleary, E. M., Byron, R. K., Hinely, K. A., Talley, A. W., Costantine, M. M., & Rood, K. M. (2020). Subcutaneous buprenorphine extended-release use among pregnant and postpartum women. Obstetrics and Gynecology, 136(5), 902–903. https://doi.org/10.1097/AOG.0000000000004126
   PubMed Web of Science ®Google Scholar
• Cotton, A. J., Lo, K., Kurtz, F. B., & Waldbauer, L. (2021). Extended-release buprenorphine outcomes among treatment resistant veterans. The American Journal of Drug and Alcohol Abuse, 48(3), 1–4. https://doi.org/10.1080/00952990.2021.1992773
   PubMed Web of Science ®Google Scholar
• Crotty, K., Freedman, K. I., & Kampman, K. M. (2020). Executive summary of the focused update of the ASAM national practice guideline for the treatment of opioid use disorder. Journal of Addiction Medicine, 14(2), 99–112. https://doi.org/10.1097/ADM.0000000000000635
   PubMed Web of Science ®Google Scholar
• Dunlop, A. J., White, B., Roberts, J., Cretikos, M., Attalla, D., Ling, R., Searles, A., Mackson, J., Doyle, M. F., McEntyre, E., Attia, J., Oldmeadow, C., Howard, M. V., Murrell, T., Haber, P. S., & Lintzeris, N. (2022). Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings. Addiction, 117(2), 382–391. https://doi.org/10.1111/add.15627
   PubMed Web of Science ®Google Scholar
• Farrell, M., Shahbazi, J., Byrne, M., Grebely, J., Lintzeris, N., Chambers, M., Larance, B., Ali, R., Nielsen, S., Dunlop, A., Dore, G. J., McDonough, M., Montebello, M., Nicholas, T., Weiss, R., Rodgers, C., Cook, J., Degenhardt, L., & CoLAB study team. (2022). Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. The International Journal on Drug Policy, 100, 103492. https://doi.org/10.1016/j.drugpo.2021.103492
   PubMed Web of Science ®Google Scholar
• Gilman, M., Li, L., Hudson, K., Lumley, T., Myers, G., Corte, C., & Littlewood, R. (2018). Current and future options for opioid use disorder: A survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine. Patient Preference and Adherence, 12, 2123–2129. https://doi.org/10.2147/PPA.S180641
   PubMed Web of Science ®Google Scholar
• Grant, M. J., & Booth, A. (2009). A typology of reviews: An analysis of 14 review types and associated methodologies. Health Information and Libraries Journal, 26(2), 91–108. https://doi.org/10.1111/j.1471-1842.2009.00848.x
   PubMed Web of Science ®Google Scholar
• Haight, B. R., Learned, S. M., Laffont, C. M., Fudala, P. J., Zhao, Y., Garofalo, A. S., Greenwald, M. K., Nadipelli, V. R., Ling, W., Heidbreder, C., & RB-US-13-0001 Study Investigators. (2019). Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 393(10173), 778–790. https://doi.org/10.1016/S0140-6736(18)32259-1
   PubMed Web of Science ®Google Scholar
• Johnson, B., Flensburg, O. L., & Capusan, A. J. (2022). Patient perspectives on depot buprenorphine treatment for opioid addiction - a qualitative interview study. Substance Abuse Treatment, Prevention, and Policy, 17(1), 40. https://doi.org/10.1186/s13011-022-00474-2
   PubMed Web of Science ®Google Scholar
• Jones, C. M., & McCance-Katz, E. F. (2019). Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug and Alcohol Dependence, 197, 78–82. https://doi.org/10.1016/j.drugalcdep.2018.12.030
   PubMed Web of Science ®Google Scholar
• Jones, A. K., Ngaimisi, E., Gopalakrishnan, M., Young, M. A., & Laffont, C. M. (2021). Population pharmacokinetics of a monthly buprenorphine depot injection for the treatment of opioid use disorder: A combined analysis of phase II and phase III trials. Clinical Pharmacokinetics, 60(4), 527–540. https://doi.org/10.1007/s40262-020-00957-0
   PubMed Web of Science ®Google Scholar
• Kenney, S. R., Anderson, B. J., Bailey, G. L., & Stein, M. D. (2018). Buprenorphine treatment formulations: Preferences among persons in opioid withdrawal management. Journal of Substance Abuse Treatment, 94, 55–59. https://doi.org/10.1016/j.jsat.2018.08.011
   PubMed Web of Science ®Google Scholar
• Larance, B., Bruno, R., Lintzeris, N., Degenhardt, L., Black, E., Brown, A., Nielsen, S., Dunlop, A., Holland, R., Cohen, M., & Mattick, R. P. (2016). Development of a brief tool for monitoring aberrant behaviours among patients receiving long-term opioid therapy: The Opioid-Related Behaviours in Treatment (ORBIT) scale. Drug and alcohol dependence, 159, 42–52. https://doi.org/10.1016/j.drugalcdep.2015.11.026
   PubMed Web of Science ®Google Scholar
• Larance, B., Degenhardt, L., Grebely, J., Nielsen, S., Bruno, R., Dietze, P., Lancaster, K., Larney, S., Santo, T., Jr., Shanahan, M., Memedovic, S., Ali, R., & Farrell, M. (2020). Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. Addiction, 115(7), 1295–1305. https://doi.org/10.1111/add.14941
   PubMed Web of Science ®Google Scholar
• Lee, J. D., Malone, M., McDonald, R., Cheng, A., Vasudevan, K., Tofighi, B., Garment, A., Porter, B., Goldfeld, K. S., Matteo, M., Mangat, J., Katyal, M., Giftos, J., & MacDonald, R. (2021). Comparison of treatment retention of adults with opioid addiction managed with extended-release buprenorphine vs daily sublingual buprenorphine-naloxone at time of release from jail. JAMA Network Open, 4(9), e2123032. https://doi.org/10.1001/jamanetworkopen.2021.23032
   PubMed Web of Science ®Google Scholar
• Ling, W., Nadipelli, V. R., Solem, C. T., Ronquest, N. A., Yeh, Y.-C., Learned, S. M., Mehra, V., & Heidbreder, C. (2019). Patient-centered outcomes in participants of a buprenorphine monthly depot (BUP-XR) double-blind, placebo-controlled, multicenter, phase 3 study. Journal of Addiction Medicine, 13(6), 442–449. https://doi.org/10.1097/ADM.0000000000000517
   PubMed Web of Science ®Google Scholar
• Ling, W., Nadipelli, V. R., Solem, C. T., Ronquest, N. A., Yeh, Y.-C., Learned, S. M., Mehra, V., & Heidbreder, C. (2020). Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study. Journal of Substance Abuse Treatment, 110, 1–8. https://doi.org/10.1016/j.jsat.2019.11.004
   PubMed Web of Science ®Google Scholar
• Ling, W., Shoptaw, S., & Goodman-Meza, D. (2019). Depot buprenorphine injection in the management of opioid use disorder: From development to implementation. Substance Abuse and Rehabilitation, 10, 69–78. https://doi.org/10.2147/SAR.S155843
   PubMed Web of Science ®Google Scholar
• Lintzeris, N., Dunlop, A. J., Haber, P. S., Lubman, D. I., Graham, R., Hutchinson, S., Arunogiri, S., Hayes, V., Hjelmström, P., Svedberg, A., Peterson, S., & Tiberg, F. (2021). Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: A randomized clinical trial. JAMA Network Open, 4(5), e219041. https://doi.org/10.1001/jamanetworkopen.2021.9041
   PubMed Web of Science ®Google Scholar
• Lofwall, M. R., Walsh, S. L., Nunes, E. V., Bailey, G. L., Sigmon, S. C., Kampman, K. M., Frost, M., Tiberg, F., Linden, M., Sheldon, B., Oosman, S., Peterson, S., Chen, M., & Kim, S. (2018). Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: A randomized clinical trial. JAMA Internal Medicine, 178(6), 764–773. https://doi.org/10.1001/jamainternmed.2018.1052
   PubMed Web of Science ®Google Scholar
• Martin, R. A., Berk, J., Rich, J. D., Kang, A., Fritsche, J., & Clarke, J. G. (2022). Use of long-acting injectable buprenorphine in the correctional setting. Journal of Substance Abuse Treatment, 142, 108851. https://doi.org/10.1016/j.jsat.2022.108851
   PubMed Web of Science ®Google Scholar
• Martin, E., Maher, H., McKeon, G., Patterson, S., Blake, J., & Chen, K. Y. (2022). Long-acting injectable buprenorphine for opioid use disorder: A systematic review of impact of use on social determinants of health. Journal of Substance Abuse Treatment, 139, 108776. https://doi.org/10.1016/j.jsat.2022.108776
   PubMed Web of Science ®Google Scholar
• Matheson, C., Foster, R., Schofield, J., & Browne, T. (2022). Long-acting depot buprenorphine in people who are homeless: Views and experiences. Journal of Substance Abuse Treatment, 139, 108781. https://doi.org/10.1016/j.jsat.2022.108781
   PubMed Web of Science ®Google Scholar
• Morgan, J. R., Walley, A. Y., Murphy, S. M., Chatterjee, A., Hadland, S. E., Barocas, J., Linas, B. P., & Assoumou, S. A. (2021). Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. Drug and alcohol dependence, 225, 108764. https://doi.org/10.1016/j.drugalcdep.2021.108764
   PubMed Web of Science ®Google Scholar
• Neale, J., Tompkins, C. N. E., & Strang, J. (2019). Prolonged-release opioid agonist therapy: Qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations. Harm Reduction Journal, 16(1), 25. https://doi.org/10.1186/s12954-019-0296-4
   PubMedGoogle Scholar
• Parsons, G., Ragbir, C., D’agnone, O., Gibbs, A., Littlewood, R., & Hard, B. (2020). Patient-reported outcomes, experiences and satisfaction with weekly and monthly injectable prolonged-release buprenorphine. Substance Abuse and Rehabilitation, 11, 41–47. https://doi.org/10.2147/SAR.S266838
   PubMed Web of Science ®Google Scholar
• Pascual, F. S., Muñoz, A., Oraa, R., Flórez, G., Notario, P., Seijo, P., Gonzalvo, B., Assaf, C., Gómez, M., & Casado, M. Á. (2022). Perception of a new prolonged-release buprenorphine formulation in patients with opioid use disorder: The PREDEPO study. European Addiction Research, 28(2), 143–154. https://doi.org/10.1159/000520091
   PubMed Web of Science ®Google Scholar
• Peckham, A. M., Kehoe, L. G., Gray, J. R., & Wakeman, S. E. (2021). Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series. Journal of Substance Abuse Treatment, 126, 108316. https://doi.org/10.1016/j.jsat.2021.108316
   PubMed Web of Science ®Google Scholar
• Rolland, B., Trojak, B., Nourredine, M., Bachellier, J., Chappuy, M., Bendimerad, P., Kosim, M., Hjelmström, P., Meroueh, F., Nubukpo, P., & Brousse, G. (2021). Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone. Drug and Alcohol Dependence, 220, 108492. https://doi.org/10.1016/j.drugalcdep.2020.108492
   PubMed Web of Science ®Google Scholar
• Saillenfait, A. M., Gallissot, F., & Morel, G. (2003). Developmental toxicity of N-methyl-2-pyrrolidone in rats following inhalation exposure. Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association, 41(4), 583–588. https://doi.org/10.1016/S0278-6915(02)00300-9
   PubMed Web of Science ®Google Scholar
• Santo, T., Jr., Clark, B., Hickman, M., Grebely, J., Campbell, G., Sordo, L., Chen, A., Tran, L. T., Bharat, C., Padmanathan, P., Cousins, G., Dupouy, J., Kelty, E., Muga, R., Nosyk, B., Min, J., Pavarin, R., Farrell, M., & Degenhardt, L. (2021). Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: A systematic review and meta-analysis. JAMA Psychiatry, 78(9), 979–993. https://doi.org/10.1001/jamapsychiatry.2021.0976
   PubMed Web of Science ®Google Scholar
• Scott, C. K., Dennis, M. L., Grella, C. E., Mischel, A. F., & Carnevale, J. (2021). The impact of the opioid crisis on U.S. state prison systems. Health & Justice Justice, 9(1), 17. https://doi.org/10.1186/s40352-021-00143-9
   PubMedGoogle Scholar
• Shadowen, C., Moeller, F. G., & Martin, C. E. (2021). The use of once-monthly injectable buprenorphine for the treatment of opioid use disorder in postpartum women: A case series. Journal of Addiction Medicine, 15(4), 292–296. https://doi.org/10.1097/ADM.0000000000000835
   PubMed Web of Science ®Google Scholar
• Sivanathan, L., Logan, E., Popovski, K., Goel, A., Hauck, T., & Ladha, K. S. (2022). Acute pain management for a tibial plateau fracture shortly after a buprenorphine XR depot injection: A case report. Journal of Addiction Medicine, 16(5), 599–601. https://doi.org/10.1097/ADM.0000000000000965
   PubMed Web of Science ®Google Scholar
• Soyka, M., & Groß, G. (2021). Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series. The American Journal of Drug and Alcohol Abuse, 47(5), 599–604. https://doi.org/10.1080/00952990.2021.1963757
   PubMed Web of Science ®Google Scholar
• Stein, M. D., VanNoppen, D., Herman, D. S., Anderson, B. J., Conti, M., & Bailey, G. L. (2022). Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine. Journal of Substance Abuse Treatment, 136, 108661. https://doi.org/10.1016/j.jsat.2021.108661
   PubMed Web of Science ®Google Scholar
• Tiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., Tanskanen, A., & Taipale, H. (2017). Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry, 74(7), 686–693. https://doi.org/10.1001/jamapsychiatry.2017.1322
   PubMed Web of Science ®Google Scholar
• Tompkins, C. N. E., Neale, J., & Strang, J. (2019). Opioid users’ willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder. Journal of Substance Abuse Treatment, 104, 64–71. https://doi.org/10.1016/j.jsat.2019.06.007
   PubMed Web of Science ®Google Scholar
• Towers, C. V., & Deisher, H. (2020). Subcutaneous extended-release buprenorphine use in pregnancy. Case Reports in Obstetrics and Gynecology, 2020, 3127676. https://doi.org/10.1155/2020/3127676
   PubMedGoogle Scholar
• Treloar, C., Lancaster, K., Gendera, S., Rhodes, T., Shahbazi, J., Byrne, M., Degenhardt, L., & Farrell, M. (2022). Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot. The International Journal on Drug Policy, 107, 103788. https://doi.org/10.1016/j.drugpo.2022.103788
   PubMed Web of Science ®Google Scholar
• Wenzel, K., Selby, V., Wildberger, J., Lavorato, L., Thomas, J., & Fishman, M. (2021). Choice of extended release medication for OUD in young adults (buprenorphine or naltrexone): A pilot enhancement of the Youth Opioid Recovery Support (YORS) intervention. Journal of Substance Abuse Treatment, 125, 108306. https://doi.org/10.1016/j.jsat.2021.108306
   PubMed Web of Science ®Google Scholar
• Winhusen, T., Lofwall, M., Jones, H. E., Wilder, C., Lindblad, R., Schiff, D. M., Wexelblatt, S., Merhar, S., Murphy, S. M., Greenfield, S. F., Terplan, M., Wachman, E. M., Kropp, F., Theobald, J., Lewis, M., Matthews, A. G., Guille, C., Silverstein, M., & Rosa, C. (2020). Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations. Contemporary Clinical Trials, 93, 106014. https://doi.org/10.1016/j.cct.2020.106014
   PubMed Web of Science ®Google Scholar